Literature DB >> 1689420

Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis.

A Kahan1, J Y Devaux, B Amor, C J Menkès, S Weber, F Guérin, A Venot, G Strauch.   

Abstract

Left ventricular dysfunction in systemic sclerosis may be due in part to myocardial ischemia caused by a disturbance in coronary microcirculation. We evaluated the pharmacodynamic effect of the calcium channel blocker nicardipine on left ventricular function assessed by radionuclide ventriculography in 20 patients with systemic sclerosis. Resting gated, blood-pool images were obtained at baseline and 90 min after 40 mg of oral nicardipine. The mean (+/- SEM) left ventricular ejection fraction significantly increased from 65.4 +/- 2.3% at baseline to 71.3 +/- 2.3% after nicardipine (p less than 0.005). The mean global defect score significantly decreased from 2.90 +/- 0.73 without nicardipine to 1.50 +/- 0.52 with nicardipine (p less than 0.01). The mean number of left ventricular sectors with severe hypokinesis significantly decreased from 0.80 +/- 0.24 at baseline to 0.20 +/- 0.09 after nicardipine (p less than 0.05). No significant side effects were observed with nicardipine. These results demonstrate short-term improvement in left ventricular function with nicardipine in patients with systemic sclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689420     DOI: 10.1097/00005344-199002000-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

Review 2.  Cardiac manifestations in systemic sclerosis.

Authors:  Sevdalina Lambova
Journal:  World J Cardiol       Date:  2014-09-26

3.  Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis.

Authors:  O Vignaux; Y Allanore; C Meune; O Pascal; D Duboc; S Weber; P Legmann; A Kahan
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

Review 4.  Nicardipine. A review of its pharmacology and therapeutic efficacy in older patients.

Authors:  J E Frampton; D Faulds
Journal:  Drugs Aging       Date:  1993 Mar-Apr       Impact factor: 3.923

Review 5.  The heart in systemic sclerosis.

Authors:  Virginia Steen
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

Review 6.  The heart in scleroderma.

Authors:  Hunter C Champion
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

7.  Case 3: - congestive heart failure in male with systemic sclerosis.

Authors:  Caio Bosquiero Zanetti; Mariana Bittar Lopes; André Marun Lyrio; Pompeu Ribeiro de Campos; Rubens Bonfiglioli; Maria Aparecida Barone Teixeira
Journal:  Arq Bras Cardiol       Date:  2013-07       Impact factor: 2.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.